<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aptevo Therapeutics Inc. — News on 6ix</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc</link>
<description>Latest news and press releases for Aptevo Therapeutics Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 03 Feb 2026 13:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aptevo-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835474d78dffbe2df0e3582.webp</url>
<title>Aptevo Therapeutics Inc.</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc</link>
</image>
<item>
<title>Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-announces-executive-leadership-transitions-130500420</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-announces-executive-leadership-transitions-130500420</guid>
<pubDate>Tue, 03 Feb 2026 13:05:00 GMT</pubDate>
<description>Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond SEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage ...</description>
</item>
<item>
<title>Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-secures-60-million-130500872</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-secures-60-million-130500872</guid>
<pubDate>Fri, 09 Jan 2026 13:05:00 GMT</pubDate>
<description>Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of key clinical and preclinical milestones SEATTLE, WA / ACCESS Newswire / January 9, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), ...</description>
</item>
<item>
<title>Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-announces-1-18-130500639</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-announces-1-18-130500639</guid>
<pubDate>Fri, 26 Dec 2025 13:05:00 GMT</pubDate>
<description>SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform ...</description>
</item>
<item>
<title>Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split </title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-announces-1-for-18-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-announces-1-for-18-reverse-stock-split</guid>
<pubDate>Fri, 26 Dec 2025 05:00:00 GMT</pubDate>
<description>SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel</description>
</item>
<item>
<title>Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-highlights-compelling-safety-130500886</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-highlights-compelling-safety-130500886</guid>
<pubDate>Tue, 09 Dec 2025 13:05:00 GMT</pubDate>
<description>100% of patients in Cohorts 1-3 remain free of cytokine release syndrome CRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care SEATTLE, WA / ACCESS Newswire ...</description>
</item>
<item>
<title>Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-debuts-first-trispecific-antibody-130500424</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-debuts-first-trispecific-antibody-130500424</guid>
<pubDate>Mon, 10 Nov 2025 13:05:00 GMT</pubDate>
<description>First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting SEATTLE, WASHINGTON / ACCESS Newswire / November 10, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage ...</description>
</item>
<item>
<title>Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-reports-3q25-financial-130500122</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-reports-3q25-financial-130500122</guid>
<pubDate>Thu, 06 Nov 2025 13:05:00 GMT</pubDate>
<description>89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid ...</description>
</item>
<item>
<title>Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-presenting-scientific-clinical-updates-122000245</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-presenting-scientific-clinical-updates-122000245</guid>
<pubDate>Wed, 08 Oct 2025 12:20:00 GMT</pubDate>
<description>SEATTLE, WASHINGTON / ACCESS Newswire / October 8, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific and trispecific immuno-oncology therapeutics, today announced ...</description>
</item>
<item>
<title>Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/mipletamig-delivers-100-remission-rate-123000521</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/mipletamig-delivers-100-remission-rate-123000521</guid>
<pubDate>Tue, 16 Sep 2025 12:30:00 GMT</pubDate>
<description>No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerability Trial progressing efficiently, Cohort 4 open for enrollment SEATTLE, WA / ACCESS Newswire / September ...</description>
</item>
<item>
<title>Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-unveils-two-next-generation-124500613</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-unveils-two-next-generation-124500613</guid>
<pubDate>Thu, 04 Sep 2025 12:45:00 GMT</pubDate>
<description>New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive cells Mipletamig-driven clinical validation ...</description>
</item>
<item>
<title>Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-highlights-apvo442-cd3-directed-120500919</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-highlights-apvo442-cd3-directed-120500919</guid>
<pubDate>Wed, 13 Aug 2025 12:05:00 GMT</pubDate>
<description>Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3 portfolio targeting both hematologic ...</description>
</item>
<item>
<title>Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-reports-2q25-financial-120500426</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-reports-2q25-financial-120500426</guid>
<pubDate>Mon, 11 Aug 2025 12:05:00 GMT</pubDate>
<description>Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types CD3 bispecific portfolio now includes three candidates ...</description>
</item>
<item>
<title>Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-announces-closing-of-dollar8-million-offering-priced-at-the-market-under-nasdaq-rules</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-announces-closing-of-dollar8-million-offering-priced-at-the-market-under-nasdaq-rules</guid>
<pubDate>Fri, 20 Jun 2025 04:00:00 GMT</pubDate>
<description>SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-announces-8-million-145200877</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-announces-8-million-145200877</guid>
<pubDate>Wed, 18 Jun 2025 14:52:00 GMT</pubDate>
<description>SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, ...</description>
</item>
<item>
<title>Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/mipletamig-demonstrates-compelling-clinical-activity-120100638</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/mipletamig-demonstrates-compelling-clinical-activity-120100638</guid>
<pubDate>Wed, 18 Jun 2025 12:01:00 GMT</pubDate>
<description>85% remission rate observed in evaluable frontline AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed among evaluable patients; safety profile remains ...</description>
</item>
<item>
<title>Aptevo Participating in the BIO International Convention</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-participating-bio-international-convention-120500072</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-participating-bio-international-convention-120500072</guid>
<pubDate>Fri, 13 Jun 2025 12:05:00 GMT</pubDate>
<description>SEATTLE, WA / ACCESS Newswire / June 13, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, ...</description>
</item>
<item>
<title>Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-announces-1-20-120500797</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-announces-1-20-120500797</guid>
<pubDate>Thu, 22 May 2025 12:05:00 GMT</pubDate>
<description>SEATTLE, WA / ACCESS Newswire / May 22, 2025 /Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares of common stock, par value $0.001 per share ("Common ...</description>
</item>
<item>
<title>Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-reports-1q25-financial-120500125</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-reports-1q25-financial-120500125</guid>
<pubDate>Thu, 15 May 2025 12:05:00 GMT</pubDate>
<description>9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials Mipletamig triplet combination continues to outperform standard doublet benchmark No cytokine release syndrome observed in the ongoing RAINIER trial: ...</description>
</item>
<item>
<title>Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-provides-program-bispecific-124500441</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-provides-program-bispecific-124500441</guid>
<pubDate>Thu, 08 May 2025 12:45:00 GMT</pubDate>
<description>As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In preclinical studies, APVO711 demonstrates dual anti-cancer ...</description>
</item>
<item>
<title>Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-announces-closing-2-200500576</link>
<guid isPermaLink="true">https://6ix.com/company/aptevo-therapeutics-inc/news/aptevo-therapeutics-announces-closing-2-200500576</guid>
<pubDate>Tue, 22 Apr 2025 20:05:00 GMT</pubDate>
<description>SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® ...</description>
</item>
</channel>
</rss>